Anthony Vecchione
The funds will be used to expand the company's enterprise-grade platform, aiOS, and accelerate the development of CARE, a clinical-grade foundation model.
The company aims to simplify the Medicaid enrollment and recertification process and will use the funds to expand into new states and scale its infrastructure.
The company will utilize the funds to accelerate the development of its clinical diagnostic platform and expand its partnerships with pharmaceutical and biotechnology firms.
The company offers mail-in semen analysis and vasectomy testing.
The new firm will offer partners an expanded range of methods and workflows for small-molecule and peptide drug discovery.
Hippocratic AI will integrate its generative AI agents to support triage and patient intake.
Patients will have 24/7 access to personalized speech, language and cognitive therapies.
The company will use the funds to augment key content partnerships.
The company will use the funds to move into the female health space and increase screening and preventive care.
The funds will be used to increase the development of GAIA-based Alzheimer's disease drugs and widen the pipeline of blockbuster drug candidates.